Escherichia Coli Nissle

You take a probiotic capsule every morning and have no idea whether a strain-specific signal is reaching your colon. This test answers that one narrow question for a single organism: it looks in your stool for DNA from Escherichia coli Nissle 1917 (EcN). This bacterial strain is sold as Mutaflor. Detected means strain-specific DNA was found in that sample. Not detected means it was not found, which can reflect timing, low abundance, or assay limits.

That is a smaller claim than most gut tests make. This is a research-grade measurement without standardized clinical cutoffs, and finding the strain in stool does not tell you your gut is healthier. It tells you whether this probiotic left a detectable trace.

What This Strain Actually Is

E. coli Nissle 1917 is a strain of E. coli. E. coli is the same species that includes food-poisoning strains, urinary-infection strains, and harmless gut residents. What separates them is the genes they carry. This strain lacks enterotoxins and alpha-hemolysin, toxins found in some disease-causing E. coli. It does carry fitness traits: microcins that suppress competing bacteria, siderophores that scavenge iron, and fimbriae that help it grip the intestinal wall.

It was isolated during World War I and has been sold as a probiotic for decades. It is not something your body makes. During dosing, it can survive passage through the gut and show up in stool. After dosing stops, most adults clear it within weeks, though a minority still carry it months later.

This matters for reading your result. A detection here is evidence of exposure, not a measurement of your own physiology. Nobody has a natural baseline level of Nissle 1917.

Why Standard Stool Panels Miss It

If you have had a gastrointestinal PCR panel run, it did not look for this. Commercial syndromic panels and hospital stool PCR tests are built to find diarrhea-causing E. coli pathotypes. They do that by hunting for virulence genes: stx1 and stx2 for Shiga toxin producers, eae for enteropathogenic strains, and lt and st for enterotoxigenic strains. Nissle has none of those genes. It is invisible to the test by design.

A clean gastrointestinal panel tells you nothing about whether your probiotic is showing up. Tracking Nissle requires strain-specific DNA targets, which is what this assay uses.

The reverse confusion happens too. Some people see "E. coli" on a stool report and assume infection. The species is a normal resident of the human large intestine. What separates a harmless or beneficial strain from a dangerous one is which genes it carries, not the name on the label.

Ulcerative Colitis: Where the Human Evidence Sits

The strongest human data for EcN is in maintaining remission in ulcerative colitis. A randomized trial in 327 adults found the probiotic held remission roughly as well as mesalazine. Mesalazine is a standard 5-aminosalicylic acid drug used for that purpose. Pooling that trial with a second head-to-head trial, 452 patients in total, Cochrane reviewers found no difference in relapse between the probiotic and 5-ASA, and a 2025 meta-analysis reproduced that null difference.

The caveats travel with the result. Reviewers graded this comparison as very low certainty evidence, the trials were small and at risk of bias, and the mesalazine dose used as the comparator was often 1,500 mg a day or less, below what is now recommended for maintenance. "About as good as mesalazine" is what the head-to-head trials showed, not what a large, well-dosed modern trial has confirmed.

Then there is the trial that cuts the other way. In 100 adults with active ulcerative colitis, adding EcN on top of conventional treatment left fewer people in symptomatic remission than placebo. In one subgroup, about half reached remission with EcN alone after placebo pretreatment, versus nearly nine in ten on placebo. Those are subgroup numbers from a single small trial, so read them as a direction rather than a precise effect. Current gastroenterology guidance recommends against probiotic monotherapy for inducing remission in mild-to-moderate ulcerative colitis.

These two findings are not in conflict once you separate the clinical situations. Holding a quiet gut quiet is a different job from calming an inflamed one. In the active-disease trial, people carrying B2-group E. coli had higher fecal calprotectin and were less likely to reach remission. Fecal calprotectin is a stool marker of gut wall inflammation. Adding more of a B2 organism to an already inflamed colon appears to be the wrong move. Maintenance is where the benefit shows up.

If you're taking EcN for ulcerative colitis, that distinction should shape what you do. Using it to hold remission has trial support, with the certainty caveats above. Reaching for it during a flare does not, and the evidence points mildly the other way.

Acute Diarrhea in Young Children

A randomized trial in 113 infants and toddlers found EcN stopped acute diarrhea faster than placebo. Median time to response was 2.5 days versus 4.8 days, and 94.5% of the treated children responded compared with 67.2% on placebo. This is one of the few settings where the strain has a clean, positive randomized result.

The population matters. These were young children with acute illness, not adults taking a daily capsule for general gut health, and the finding does not transfer to that use. In wider reviews of probiotics for childhood diarrhea, this strain is not among those with the most consistent benefit.

Skin Conditions Driven From the Gut

In a small non-blinded randomized trial, 57 of 82 screened adults with inflammatory facial skin conditions entered final analysis. Adding two capsules a day for one month to diet and topical treatment improved symptoms more than diet and topical treatment alone. Serum IgA rose, and interleukin-8 fell. IgA is an antibody used at mucosal surfaces. Interleukin-8 calls inflammatory cells into tissue. The trial was short and unblinded, so treat it as promising rather than settled.

The Colibactin Question

EcN carries a stretch of DNA called the pks island. This lets it produce colibactin. In laboratory and animal work, colibactin can damage DNA in mammalian cells. A 2024 study in human intestinal organoids, lab-grown miniature gut tissue, included this exact probiotic strain and showed it producing the same DNA-damage pattern found in a subset of colorectal tumors. That is the reason researchers are building colibactin-free versions of the strain.

Before you stop your capsules, look at what happened when this was tested in people. A prospective study of 5,020 adults in a routine colorectal cancer screening program measured pks-positive E. coli in stool and compared people who turned out to have advanced colorectal findings against those who did not. Carriage was 28.6% in cases and 25.9% in controls, a difference the study could not distinguish from chance. A one-time stool measurement of pks-positive E. coli did not predict who had advanced disease.

The picture is: a real genetic capability, DNA damage in laboratory and organoid work, and no signal that carrying these organisms separates people who have advanced colorectal findings from people who do not. Laboratory work also suggests the toxin has to make direct contact with the gut lining during vulnerable periods, such as active inflammation or early life, rather than during ordinary carriage in a healthy adult gut. That is an unresolved safety question worth knowing about, not a demonstrated harm. Long-term continuous use in someone with a strong family history of colorectal cancer is a reasonable thing to raise with a gastroenterologist.

When a Result Can Mislead You

The largest problem with this measurement is that nobody has established what a normal or optimal number looks like. Absolute E. coli counts vary widely between healthy people, and studies of EcN rely on comparing the same person before and after dosing rather than against any fixed range. A single number in isolation is close to uninterpretable.

• Recent dosing: the strain usually clears after you stop taking it. In one DNA-based human study, median clearance was about one week and more than 80% of adults cleared it within three weeks. Studies that grow the organism instead of detecting its DNA are less tidy: in one healthy-volunteer trial, 4 to 7 of 20 participants per group still had viable strain in stool 12 weeks after stopping. Stopping capsules shortly before a test can turn a positive into a negative, which is a fact about timing and not about your gut.
• DNA is not the same as a living organism: PCR finds genetic material. In hospital testing, some pathogen PCR positives are culture-negative. One study found about a third of Campylobacter PCR-positive cases had negative culture. For this strain, a weak DNA signal can mean live bacteria, dead cells, or leftover DNA.
• Antibiotics: a course of antibiotics can suppress susceptible E. coli and reshape the gut bacterial community for weeks or months. Testing during or shortly after antibiotics tells you about recent antibiotic exposure, not your usual state.
• Stool sampling itself: stool contains compounds that can inhibit DNA amplification. Labs work around this with specialized extraction and controls, but results at low abundance are less reliable than results at high abundance.

Why One Reading Tells You Almost Nothing

This is a before-and-after test, not a snapshot test. Without a standardized reference range, the only comparison that carries information is you against yourself.

The useful sequence is straightforward. Test before you start the probiotic or after a washout, so you know your true baseline is negative. Start the capsules, keep the dose and timing consistent, then test again after four to six weeks of steady use. If the strain shows up the second time and did not the first, your product is leaving a stool signal. If it never appears despite consistent dosing, the product may not be arriving, the organisms may be dead, or the strain may clear too quickly for the timing you chose.

Detecting the strain confirms its DNA is present, not that it is helping. Symptom tracking and, in inflammatory bowel disease, fecal calprotectin are what tell you whether anything clinically useful is happening.

What to Do With an Unexpected Result

If you expected a positive and got a negative, check the obvious first: refrigeration, expiration date, and whether you were consistent with dosing. Repeat the test after a month of reliable use before concluding the strain will not show up. Recent antibiotics are reason enough to wait and retest later rather than draw any conclusion.

If the strain shows up and you never took it, repeat the test. Strain-specific assays are designed to avoid ordinary E. coli cross-reaction, but no DNA test is immune to contamination, sample mix-up, or a target that is not as unique as expected.

If the question is symptoms rather than product verification, pair this with tests that answer that question. Ongoing diarrhea, blood in stool, or weight loss calls for a gastrointestinal pathogen panel and fecal calprotectin. Calprotectin helps separate inflammatory bowel disease from irritable bowel syndrome. A pattern of high calprotectin with ongoing symptoms warrants a gastroenterologist and likely colonoscopy, whichever way the result reads. Persistent high-volume diarrhea, fever, or dehydration is a reason to be seen promptly rather than keep testing.